Jonathan Appleby PhD

CSO Cell and Gene Therapy

Back to Speakers

Jonathan joined GSK Rare Diseases in September 2010 where he has led the medicines development program for Strimvelis, the first approved Ex Vivo CD34 stem cell gene therapy. He is also Chief Scientific Officer for Rare Diseases Gene Therapy providing support across several gene therapy projects and advising on new investment opportunities. Prior to joining the Rare Diseases team Jonathan was part of the GSK Centre of Excellence for External Drug Discovery where for 4 years he discovered, constructed and managed drug discovery alliances with US, European and Emerging Market companies covering a diverse range of discovery platforms in indications such as oncology, neurology, respiratory and anti-infectives. He is a PhD qualified molecular biologist with two decades of pharmaceutical industry experience.